Who Paid My Doc
Thomas Demarini
Pulmonary Disease Decatur, GA Medical Doctor
NPI 1407831696 CMS profile 153952
2665 N Decatur Rd, Ste 430, Decatur, GA 30033
General payments
$59,191
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$70
Through program year 2025, Thomas Demarini of Decatur, GA is reported in the CMS Open Payments database as having received $59,191 across 594 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $70 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $25 | 1 | |
| 2024 | General | $50 | 1 | |
| 2023 | General | $1,423 | 65 | |
| 2022 | General | $37,427 | 157 | |
| 2021 | General | $10,576 | 116 | |
| 2020 | General | $2,078 | 123 | |
| 2019 | General | $7,613 | 131 |
Beside peers
- Thomas Demarini
- Pulmonary Disease median
- Middle half of Pulmonary Disease
- National median
In program year 2025, general payments to Thomas Demarini were reported at $25. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.
Show as a table
| Year | Thomas Demarini | Pulmonary Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $7,613 | $377 | $109–$1,340 | $163 |
| 2020 | $2,078 | $230 | $56–$907 | $114 |
| 2021 | $10,576 | $269 | $68–$1,072 | $132 |
| 2022 | $37,427 | $390 | $100–$1,457 | $149 |
| 2023 | $1,423 | $419 | $114–$1,659 | $160 |
| 2024 | $50 | $476 | $123–$1,818 | $164 |
| 2025 | $25 | $500 | $124–$1,893 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
213
Drug cost
$191,159
Branded share of claims
53.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Opsumit Macitentan | Brand | 11 | $131,234 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 61 | $58,083 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 42 | $884 | |
| Famotidine | Generic | 33 | $454 | |
| Gabapentin | Generic | 17 | $201 | |
| Omeprazole | Generic | 21 | $157 | |
| Azithromycin | Generic | 16 | $99 | |
| Prednisone | Generic | 12 | $48 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
594 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pulmonary Disease in Georgia
Related records
Pulmonary Disease in Georgia
Practitioners in the same specialty and state, ranked by reported value.
All Pulmonary Disease
Everyone recorded under this specialty, nationwide.
Doctors in Georgia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.